Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
McKesson $850 million acquisition of controlling interest in PRISM Vision
We are advising McKesson on the transaction
GH Research $150 million follow-on offering
We advised GH Research on the offering of shares
Maze Therapeutics $140 million IPO
The shares are listed on Nasdaq
Global pharmaceutical company in congressional inquiry
We are representing the client in an inquiry regarding certain online platforms
Ascentage Pharma $126.4 million IPO
The IPO is the first life sciences U.S. IPO of 2025 and the first life sciences company listed on the HKEX to complete a U.S…
Outlook Therapeutics $20.4 million warrant liability transaction
Certain holders agreed to exercise Outlook Therapeutics warrants at a reduced exercise price while receiving new warrants
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Intra-Cellular Therapies $14.6 billion acquisition by Johnson & Johnson
We are advising Intra-Cellular Therapies on the transaction
Royalty Pharma $1.1 billion acquisition of its external manager and $3 billion share repurchase
We are advising Royalty Pharma on the transaction
BrainAurora Medical Technology HK$583 million IPO
We advised BrainAurora on its IPO and HKEX listing